Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.53 |
| ▸ | MMP9 | P14780 | 18/20 | 0.53 |
| ▸ | MMP3 | P08254 | 17/20 | 0.53 |
| ▸ | MMP7 | P09237 | 17/20 | 0.53 |
| ▸ | MMP13 | P45452 | 16/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919122 | 1.00 | MMP1 (0.53) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL918708 | 0.99 | MMP1 (0.54) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL328472 | 0.99 | MMP1 (0.54) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779102 | 0.93 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779193 | 0.92 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL12942841 | 0.91 | MMP9 (0.44) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779159 | 0.91 | MMP1 (0.57) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL778946 | 0.90 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL14878435 | 0.90 | MMP9 (0.42) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL12905327 | 0.89 | MMP9 (0.41) | MMP1MMP9MMP3MMP7MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003812-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003812-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | MMP1 13/4885MMP9 12/4885MMP3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.